Duchenne muscular dystrophy (DMD) is one of the most common lethal genetic diseases worldwide, caused by mutations in the dystrophin (DMD) gene. Exon skipping employs short DNA/RNA-like molecules called antisense oligonucleotides (AONs) that restore the reading frame and produce shorter but functional proteins. However, exon skipping therapy faces two major hurdles: limited applicability (up to only 13% of patients can be treated with a single AON drug), and uncertain function of truncated proteins. These issues were addressed with a cocktail AON approach. While approximately 70% of DMD patients can be treated by single exon skipping (all exons combined), one could potentially treat more than 90% of DMD patients if multiple exon skipping using cocktail antisense drugs can be realized. The canine X-linked muscular dystrophy (CXMD) dog model, whose phenotype is more similar to human DMD patients, was used to test the systemic efficacy and safety of multi-exon skipping of exons 6 and 8. The CXMD dog model harbors a splice site mutation in intron 6, leading to a lack of exon 7 in dystrophin mRNA. To restore the reading frame in CXMD requires multi-exon skipping of exons 6 and 8; therefore, CXMD is a good middle-sized animal model for testing the efficacy and safety of multi-exon skipping. In the current study, a cocktail of antisense morpholinos targeting exon 6 and exon 8 was designed and it restored dystrophin expression in body-wide skeletal muscles. Methods for transfection/injection of cocktail oligos and evaluation of the efficacy and safety of multi-exon skipping in the CXMD dog model are presented.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive muscle disease characterized by progressive muscle weakness, first described by Dr. Guillaume-Benjamin-Amand Duchenne (de Boulogne) 1 . DMD is a common genetic disease affecting about 1 in 3,500 boys worldwide, with approximately 20,000 affected children born each year 2, 3 . Motor development is delayed and gait disturbances are seen in early childhood 4 , followed by wheelchair dependency at about the early teens. Death typically occurs between the ages of 20 and 30 due to respiratory or cardiac failure [5] [6] [7] [8] . There is currently no cure for DMD. Treatment with glucocorticoids can slow the progression of muscle degeneration to some degree but is associated with significant side effects, including obesity and diabetes mellitus 2, 7, 8 . DMD results from mutations in the dystrophin (DMD) gene, leading to a loss of functional dystrophin protein. DMD is an extremely large gene with over 2 million base pairs and 79 exons 9, 10 . Deletion, nonsense, and duplication mutations leading to out-of-frame mutations are the most common cause of the DMD phenotype. The regions of exons 3 -9 and exons 45 -55 are termed "mutation hotspots" as most patients have deletion mutations within these portions of the gene, leading to non-functional dystrophin in DMD patients 3, 9, [11] [12] [13] [14] [15] [16] . Dystrophin functions within the dystrophin-glycoprotein complex (DGC), which has a major role in muscle membrane stabilization. The N-and C-termini are the most important domains for function, while the central rod domain plays a less important role 3, 9, 17 . The observance of a mild phenotype associated with Becker muscular dystrophy (BMD), which mostly results from in-frame mutations within the DMD gene, inspired the application of exon skipping for treating DMD. BMD patients have a shortened, but functional, dystrophin protein that maintains both termini 3, 6, 18 . Exon skipping, in theory, can restore the reading frame, resulting in shortenedbut-functional dystrophin proteins similar to those seen in BMD 3, 19 .
Multiple types of antisense oligonucleotides (AONs) have been tested in clinical trials, including 2'O-methylated phosphorothioates (2'OMePS) and phosphorodiamidate morpholino oligomers (PMOs). Skipping exons 51 and 53 using these AONs has been examined and while results are promising, single-exon skipping has limited applicability, as it is mutation-specific 3, 19, 20, 21, [22] [23] [24] [25] [26] . Questions also remain about the stability of the resulting shortened dystrophin proteins produced from single-exon skipping 22, 23 . Additionally, some patients require more than a single exon to be skipped in order to restore the reading frame . CXMD dogs more closely mimic the human DMD phenotype than smaller animal models, like rodent, and are more reliable for toxicological assessments 3, 22, 30, 31 (Figure 2) . CXMD dogs display progressive muscle decay, gait disturbances, and cardiac and respiratory problems similar to those seen in DMD. Compared with single-exon skipping, multi-exon skipping is applicable to a much larger proportion of patients. Among the three most common mutation types (deletions, nonsense, and duplications), 80 -98% of patients could be treated through multi-exon skipping 14, 32, 33 , while 45% of all DMD patients could benefit from specifically skipping exons 45 -55 3, 19, 22, 34 .
With the development of modified morpholinos, the efficiency of AON cocktails at facilitating exon skipping has improved. Arginine-rich cellpenetrating peptide-conjugated PMOs (PPMOs), and vivo-morpholinos (vPMOs) are AON chemistries that have significantly improved cellpenetrating ability and stability 3, [35] [36] [37] [38] . Concerns remain about long-term AON toxicity; however, significant progress has been made. Chemical modifications made to morpholinos greatly decrease off-target effects and pre-clinical studies have reported no significant toxic effects 3, 22, 39, 40 . A remaining challenge for multi-exon skipping is the current requirement for each single AON to be tested for toxicity alone, as a single drug, instead of together as a cocktail 3, 19, 22, 41, 42 . In DMD studies involving both single and multi-exon skipping targeted to the heart, there has been little improvement in dystrophic heart tissue. The efficacy of morpholinos in the heart is thought to be low because of poor cell-penetrating ability. Peptide-conjugated PPMOs have improved the ability of AONs to penetrate cardiac cells, increasing the amount of functional dystrophin protein rescued in the heart 3, 19, 38 .
Here, our AON cocktail approach is discussed at length, including the design of AON sequences using ESEfinder software 43 . Protocols for dog experiments with multi-exon skipping are also described. CXMD J beagles were used for exons 6 and 8 skipping experiments. Multi-exon skipping in the CXMD dog model shows promising results, but challenges remain that need to be overcome before they are clinically applicable.
1. For maintenance of sterile conditions during survival surgery, remove hair using clippers in the area surrounding the surgery site (the hind limb). Use iodophors or chlorohexidine as a disinfectant. Use sterile drapes for the surgical site by placing and securing them over the entire animal and the operating table.
1. Wear clean scrubs, face masks, head covering, sterile gloves, and special shoes for the operating room 52, 53 .
2. Inject CXMD dogs with 20 mg/kg of thiopental sodium to anesthetize them. Use vet ointment on the eyes to prevent the eyes from drying out. 3. Use 2 -3% isoflurane inhalation to maintain general anesthesia (Figure 3) . Check muscle reflexes and monitor heart and breathing rate to assess the depth of anesthesia. The normal respiration rate (RR), heart rate (HR), and SpO 2 under general anesthesia are as follows: RR: 10 -20 breaths/min; SpO 2 : 95 -100%, HR: 80 -120 beats per minute (bpm). 4. Using a scalpel, cut the skin over the cranial tibial (CT), also known as the tibialis anterior (TA), and make a single cut approximately 5 cm longitudinally (for young adult dogs). To mark the injection sites, stitch the deep fascia using a surgical needle and surgical thread and make two stitch markers at 2 cm intervals. . Perform open muscle biopsy by removing a piece of muscle tissue approximately 2 cm in length from CT muscle using a surgical scalpel. 7. Go to step 6.5 for muscle sample preparation. 8. Using a needle, administer an intramuscular injection of 0.02 mg/kg buprenorphine hydrochloride before awakening from general anesthesia.
Lay muscle fascia and skin back over muscle and stitch these using a 3-0 absorbable thread and 3-0 nylon thread for muscle fascia and skin closure, respectively. 9. While holding the mouth open, determine whether the gag reflex has returned; when the gag reflex has returned, extubate the dog. 10. Administer 15 to 30 mg/kg cefazolin or cephalexin (antibiotics) for up to 3 days via intravenous or intramuscular injection to prevent infection. 11. Remove sutures within seven days. Do not leave the dog unattended until it has regained sufficient consciousness to maintain sternal recumbency and do not allow the dog to interact with other animals until a full recovery is made. Keep the endotracheal tubes in place as long as possible and remove them when the animal begins to chew or swallow. Monitor the animal's heart rate, respiration, and hydration to make sure they are stable and within normal limits. 12. For post-surgery care, provide analgesia for 3 days (e.g., buprenorphine 0.01 mg/kg) and nursing support, including a quiet, dark resting place, appropriate wound and bandage maintenance, a soft resting surface, rehydration with oral or parenteral fluids, and a return to normal feeding through the use of highly palatable foods or treats. If any animals require the additional medication, give an intramuscular injection of 0.3 mg/kg of butorphanol tartrate depending on the pain symptoms.
Note: Dogs in pain may bite, scratch, or guard painful regions, and if handled, may be unusually apprehensive or aggressive. In addition, pain in one limb usually results in limping or holding-up of the affected limb with attempts to use it. In such situations, give an intramuscular injection of 0.02 mg/kg of buprenorphine hydrochloride every 6 -8 hr.
Systemic Injections
Note: This procedure can be repeated weekly or biweekly for the desired number of weeks.
1. Restrain dogs manually and gently by getting the dog to lie down and then drape arms over the shoulders and hips to hold the dog in place throughout the procedure. 2. Inject AONs; 120 -240 mg/kg cocktail PMOs (40 -80 mg each AON) using a venous indwelling needle into a limb vein (known as a cephalic or a saphenous vein). The amount of AON injected depends on the experimental condition. Use an equal amount of each AON for the cocktail. 3. Use an infusion pump or syringe driver to inject 50 ml total at a rate of 2.5 ml/min for 20 min, following the manufacturer's instructions. Repeat injections weekly or biweekly (every two weeks) at least 5 times, as dystrophin expression will accumulate with repeated injections. 4. Perform blood tests weekly to examine toxicity.
1. Using a needle, collect 3 ml of blood -0.5 ml for complete blood count (CBC) and 2.5 ml for others -from one of the subcutaneous veins of the fore or hindlimb. Include CBC, gamma-glutamyl transferase (GGT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), alanine aminotransferase (ALT), creatine kinase (CK), and creatinine assessments when testing the collected blood, following manufacturer's instructions from blood test kits.
40,54
Clinical Grading of Dogs
1. Set up a video camera and record dog behavior and gait. Record the entire encounter with the dog as this will act as a reference when grading the dog; this means each video will be a different length depending on the dog's abilities and willingness. Use default recording parameters. Filming creates a record of the grading so it can be reviewed at a later date. 2. Grade gait and movement disturbances. 4. Determine muscle atrophy of the limb using the following grading scale: grade 1 = none, grade 2 = suspect hardness, grade 3 = can feel hardness or appears thin, grade 4 = between grades 3 and 5, and grade 5 = extremely thin or hard. 5. Grade drooling using the following scale: grade 1 = none, grade 2 = occasionally dribbles saliva when sitting, grade 3 = some drool when eating and drinking, grade 4 = strings of drool when eating or drinking, and grade 5 = continuous drool. 6. Grade hypertrophy of the tongue (macroglossia) using the following scale: grade 1 = none, grade 2 = slightly enlarged, grade 3 = extended outside dentition, grade 4 = enlarged and slightly thickened, and grade 5 = enlarged and thickened. 7. Grade the dog's ability to swallow using the following scale: grade 1 = no difficulty, grade 2 = takes time and effort in taking food, grade 3 = difficulty in taking food from a plate, grade 4 = difficulty in chewing, swallowing, or drinking, and grade 5 = unable to eat. 8. Calculate total grade by adding the scores from each category (except for the 15 m running test) 55 . Note: The studies should be blinded so as not to introduce bias.
Magnetic Resonance Imaging (MRI)
1. Use a 3 Tesla (3T) MRI and 18 cm diameter/18 cm length human extremity coil to obtain T2-weighted images of hind-limbs. 2. Anesthetize animals by injecting CXMD dogs with 20 mg/kg of thiopental. Use vet ointment on the eyes to prevent the eyes from drying out.
Use 2-3% isoflurane inhalation to maintain general anesthesia. 1. Check muscle reflexes and monitor heart and breathing rate to assess the depth of anesthesia. The normal respiration rate (RR), heart rate (HR) and SpO 2 under general anesthesia are as follows: RR: 10 -20 breaths/min, SpO 2 : 95 -100%, HR: 80 -120 beats per minute (bpm).
3. Use the following settings to obtain T2-weighted images: TR/TE = 4,000/85 msec, slice thickness = 6 mm, slice gap = 0 mm, field of view = 18 cm x 18 cm, matrix size = 256 x 256, and number of acquisitions = 3 during fast spin echo (Figure 4 ).
Muscle Sampling and Preparation (Necropsy)
Note: Muscles should be sampled one or two weeks after the last AON injection.
1. Inject dogs with 20 mg/kg of thiopental sodium to anesthetize them. Use vet ointment on the eyes during anesthetization to prevent drying of the eyes. 2. Use 2 -3% isoflurane inhalation to maintain anesthesia. Check muscle reflexes and monitor heart and breathing rate to assess the depth of anesthesia. The normal respiration rate (RR), heart rate (HR) and SpO 2 under general anesthesia are as follows: RR: 10 -20 breaths/min; SpO 2 : 95 -100%, HR: 80 -120 bpm.
1. Euthanize dogs by exsanguination under general anesthesia (for necropsy only). Use exsanguination under deep general anesthesia to avoid the effects caused by blood-derived factors in the molecular analysis (e.g., cardiac muscles).
3. Dissect the following muscles ( Figure 5) 
Immunohistochemistry
1. Remove prepared slides from storage and place them in a moisture chamber to keep the slides separated and maintain moisture. Fill the moisture chamber so that the bottom is just covered with water (approximately 1 mm of water). 2. Air-dry for 0.5 hr. Draw a square enclosing the muscle sample on the slide using a hydrophobic barrier pen. 3. Add 15% goat serum in phosphate buffered saline (PBS) and incubate for 2 hr at RT In blocking reagent. 4. Add anti-dystrophin rod domain (DYS-1) mouse monoclonal primary antibody, or C-terminal monoclonal antibody (DYS-2) for dog dystrophin staining (1:150 dilution). Dilute using a blocking agent in 1.25 ml of PBS. Incubate O/N in a refrigerator a 4 °C.
Wash with PBS for 5 min, repeated three times. Add secondary antibody Alexa 594 goat antibody against mouse IgG1 (for DYS-2) or IgG2
(for DYS-1) (1:2,500). Dilute with a blocking reagent in PBS containing 0.1% octyl phenol ethoxylate. Incubate for 0.5 hr at RT. 6. Wash with PBS for 5 min, three times. Allow slide to dry. Add 1 -2 drops (3 ng/ml) of 4',6-diamidino-2-phenylindole (DAPI) mounting solution.
Using tweezers, place a glass slip over the top of the sections, avoiding bubbles. 7. View dystrophin-(DYS-1/DYS-2) positive fibers under a fluorescent microscope at 594 nm at 20X magnification.
Western Blotting
1. Add collected muscle sections from cryo-sectioning to 150 µl of sample buffer on ice. 2. Using a hand homogenizer, briefly homogenize the protein samples. Heat samples in a 1.5 ml tube in a heating block incubator at 95 °C for 3 -5 min. Centrifuge at 16,500 × g for 15 min and collect the supernatant. 3. Store aliquots of the supernatant at -70 °C. Use distilled water to dilute to 100x. 4. Determine protein concentration using a commercial kit according to manufacturer's protocol. Add 2x Laemmli SDS-loading buffer to samples and heat for 3 min at 95 °C. 5. Load samples into 3 -8% Tris-acetate gel before running it for 3 hr at 150 V. Include several diluted wild-type (WT) samples (e.g., 1%, 10%, and 50%) for quantification. Less than 1% WT levels of dystrophin should be detected with this method. 6. Place the gel in cathode buffer for 20 min. During this time, take nine pieces of filter paper and put them in the transfer buffers (3 papers in the cathode buffer [+], the anode buffer ( [-] , and the concentrated anode buffer [--], respectively). This describes a semi-dry transfer method which increases sensitivity (Figure 6 ). 7. Soak a PVDF membrane in methanol for 20 sec and then place in the anode buffer.
Set up the gel with the membrane for semi-dry transfer and allow it to run 1.5 hr at 400 mA in RT or in a cold room. 8. Wash the membrane with PBS. Incubate the membrane in a mixture of PBS with Tween 20 (PBST) and 5% milk powder for 2 hr. 9. Dilute DYS-1 (primary antibody) in PBST and 5% milk powder mixture to a 1:100 dilution. Add it to the membrane and let it incubate for at least 1 hr. Wash three times with 100 ml PBST for 15 min each. 10. Add 65 µl/lane of HRP conjugated secondary antibody (anti-mouse IgG2a for DYS1) at 1:5,000 dilution for 1 hr at RT in a dark area. Then, wash with three times with 200 ml PBST for 20 min. Mix solutions from a detection kit as directed. Incubate for 1 min. 11. Develop film to detect bands and analyze with ImageJ software 48, 57, 58 .
In Vivo Experiments
To compare the efficiency of various AON treatment conditions, CXMD dogs (0.5 -5 years old) were injected once with 1.2 mg Ex6A or a cocktail of Ex6A, Ex6B, and Ex8A at various dosages. Two weeks after the injection, muscle samples were collected and stained with DYS-1 to compare the number of dystrophin-positive fibers. All cocktail-treated samples showed increased dystrophin expression compared to NT samples. Dystrophin-positive fibers increased with AON dosage (Figure 9) . Following systemic injection, wild-type (WT), NT, and cocktail-treated CXMD muscle samples were stained with DYS-1 (Figure 10) . Cocktail-treated CXMD dogs showed increased dystrophin expression compared to NT CXMD dogs, both in CT and heart muscle samples. However, AON-treated skeletal muscle (CT) showed much higher expression of dystrophin compared to treated cardiac muscle. An immunoblot comparing WT, NT, and various morpholino cocktail-treated muscles led to the same conclusion. There was also a large range of dystrophin expression in the treated skeletal muscle samples (Figure 10 ). Hematoxylin and eosin (HE) staining revealed that treated CXMD dogs showed improved histopathology, with a significant decrease in centrally-nucleated fibers (CNF) in comparison to NT CXMD dogs (Figure 11) . This indicates there is more degeneration/regeneration occurring in the NT dog, a sign of dystrophic muscle pathology. Additionally, treated dogs had faster running times and improved scores on the clinical grading scale. Treated CXMD dogs showed better scores than NT CXMD dogs in all categories (Figure 12 ). . Please click here to view a larger version of this figure.
Antisense Oligonucleotide Nucleotide Sequence
Ex6A GTTGATTGTCGGACCCAGCTCAGG Ex6B ACCTATGACTGTGGATGAGAGCGTT Ex8A CTTCCTGGATGGCTTCAATGCTCAC 
Discussion
Exon skipping is a promising therapeutic technique for the treatment of DMD. Both in vitro and in vivo experiments have shown that multi-exon skipping is feasible. Here, the use of the CXMD dog model is discussed. First, AONs were designed using the Rescue-ESE and ESEfinder programs to target dystrophin exons 6 -8. The 2'OMePS AON chemistry was used for CXMD myoblast transfection and the morpholino AON backbone chemistry was chosen for in vivo experiments. vPMOs are more efficient than unmodified PMOs but due to their higher toxicity they are not suitable for systemic injections. RNA extraction, RT-PCR, and cDNA sequencing were performed on the CXMD myoblasts. Dogs injected with the PMO cocktail were clinically graded to assess any improvement in clinical symptoms. After the dogs were humanely euthanized, muscle samples were taken and prepared for cryo-sectioning. The half-life of dystrophin protein induced by AONs is believed to be approximately 1 -2 months. Young adult dogs were used in this study, although these experiments can be done with neonatal dogs and older dogs (>5 years old). Prepared muscle sections were used to evaluate histopathology and assess dystrophin protein rescue through Western blotting and immunohistochemistry 48 .
It is important to ensure that the volume of the PMO solution is correct before injections; failing to do so will have significant effects on results. During intramuscular injections, sufficient pressure is required to enter the muscle fibers. Monitoring of dog health and inspection of the surgery site are important for troubleshooting. To monitor animal health, weekly blood tests and weighing should be performed. After euthanization of the animal and preparation of muscle samples, a critical step for ensuring sensitivity in detecting dystrophin protein is to use both the Tris-acetate gel and semi-dry blotting method during the Western blotting procedure.
As shown in the representative results, myoblasts treated with Ex6A, Ex6B, Ex8A, and the cocktail (containing Ex6A, Ex6B, Ex8A, and Ex8B) produced in-frame DMD products. Since Ex8B produced no exon-skipped products, it was not used in subsequent in vivo experiments. cDNA sequencing showed that exons 6 -9 skipping occurred and immunocytochemistry with DYS-2 staining showed restored dystrophin expression in treated samples. AON-treated dogs showed a significant increase in dystrophin-positive fibers. This indicates that exons 6 -8 were being skipped and a shortened protein was produced. The amount of dystrophin-positive fibers increased when a cocktail of AONs was used and was proportional to AON dosage. Immunoblots showed increased dystrophin expression in systemic morpholino-treated dogs. Skeletal muscle had variable levels of dystrophin fibers; however, morpholino-treated heart tissue showed little improvement in dystrophin expression. Since dystrophin has a high molecular weight (427 kDa), detection of low amounts of dystrophin can be difficult. For the best results, Tris-acetate gel and the semi-dry transfer method were used. HE staining showed improved histopathology in the morpholino-treated dogs. Centrallynucleated fibers (CNFs) are a sign of unhealthy muscle and represent cycles of muscle degeneration and regeneration. Morpholino-treated CXMD dogs showed a decrease in the percentage of CNFs in comparison to non-treated CXMD dogs. Clinical grading revealed an improvement in symptoms, such as increased walking and running ability, in morpholino-treated animals. The hardness of muscles is believed to reflect muscle atrophy, thus, it was included in the grading scheme 59 . The hardness of thigh (hind-limb) muscles was evaluated; however, we excluded cranial sartorius muscles because they tend to exhibit hypertrophy rather than atrophy in CXMD. Treated dogs showed lower grading scores and had faster times on the 15 m running test. Improved times on the 15 m test are indicative of improved muscle function 40 . Higher overall grading scores indicate poor health and increased muscle atrophy.
While these results are promising, multi-exon skipping still presents many challenges that will need to be overcome before the technique has clinical applicability. Cardiac tissue still displays reduced uptake of AONs, likely due to the difference in cellular trafficking between cardiac and skeletal tissue. No toxic effects have been observed in animals under current dosage regimens; however, more work needs to be done to assess long-term toxicity before the use of AON cocktails can move to clinical trials. It is difficult to gain approval for AON cocktail drugs because regulatory agencies define each AON sequence as a unique drug. This means that each sequence in a cocktail would need to be individually tested for safety, requiring more time and more money. Another barrier to the use of multi-exon skipping in a clinical setting is a large amount of intermediate protein products produced with unknown functions. These proteins can potentially lead to unpredictable side-effects, depending on the individual mutation 22 . Additionally, the mutation patterns available within current dystrophic dog models are limited. There are few naturally-occurring mutations, and not all mutations are useful for studying multi-exon skipping. The dystrophic pig model promises to be a good alternative for future DMD exon skipping studies 33, 34 .
The DMD dog models have some advantages over other DMD models. Being a larger animal model, clinical grading and MRI are possible, allowing for more detailed analysis. Since dogs are large animals they are also more suited for toxicology studies and more closely represent the human disease in comparison to the mouse model. Dog models also have DMD gene sequences that are more similar to humans 23, 34, 45 .
Although technically challenging, the multi-exon skipping approach could ultimately benefit >90% of DMD patients 24 . This makes it a much better alternative to single-exon skipping, as single-exon skipping is only applicable to a small subset of patients. In addition, multi-exon skipping will enable us to select the deletion patterns that optimize the functionality of the shortened dystrophin proteins. For example, deletion of DMD exons 45 -55 is associated with exceptionally mild symptoms or asymptomatic individuals 14, 19, [60] [61] [62] [63] . The multi-exon skipping of exons 45 -55 has already been demonstrated in a mouse model of DMD with an exon 52 deletion (mdx52) using systemic injections of vPMOs 22, 26 . The use of cocktail vPMOs has also been demonstrated in other forms of muscular dystrophy, such as Fukuyama congenital muscular dystrophy (FCMD). FCMD is caused by exon trapping, in which aberrant mRNA splicing is caused by retrotransposon insertion. vPMOs have been shown to rescue the splicing pattern in both an FCMD mouse model and in human cell lines 64 . Next-generation AON chemistries exhibiting higher efficacy and lower toxicity would facilitate the effective translation of the multi-exon skipping approach into clinical application. Additionally, multi-exon skipping could potentially be applied to other genetic disorders, such as the dysferlinopathies 24, 65 .
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